BioSpace News Archive

Carisma Therapeutics announced that Steven Kelly, President and CEO, has been named Ernst & Young Entrepreneur of the Year® 2022 Greater Philadelphia Award Winner.

Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) seeking approval for tebipenem HBr oral tablets for treatment of adult patients with complicated urinary tract infection (cUTI), including pyelonephritis.

Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that the Company has extended its Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) .

New BVA Device Aims to Possess Gold Standard Accuracy and Reproducibility with Increased Safety, Access, Ease of Use, and Frequency of Testing Afforded by a Non-Nuclear Tracer.

Evommune, Inc., a clinical stage, biotechnology company dedicated to the development of transformative medicines for inflammatory diseases, today announced the appointment of Gregory S. Moss, Esq. , as chief corporate strategy and legal officer.

Proceeds will accelerate a robust R&D pipeline, commercial partnerships and clinical activities led by leading institutional and strategic investors.

Data Presented at 2022 EASL International Liver Conference TM and First International Extracellular Matrix Pharmacology Congress.

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced the appointment of Dr. Michael Sumner, MB BS, MBA, as Chief Medical Officer (CMO).

Ambys Medicines , a company pioneering cell-replacement therapies for patients with liver disease, today announced the formation of its clinical and scientific advisory boards comprising leading clinical experts in liver disease and hepatocyte transplantation, and world-class scientists pioneering cell and gene technologies.

Acer Therapeutics Inc. (Nasdaq: ACER), a clinical stage pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced the initiation of patient screening in its Phase 3 clinical trial of EDSIVO™.